Skip to main navigation

About
- Team
- Contact
Research & Development
Pipeline
- RMC-4630
- Mutant RAS
- SOS1
- RMC-5552
Investors
Careers

Press Releases

Press Releases

Year

March 11, 2021

Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021

March 9, 2021

Revolution Medicines to Participate in Upcoming Investor Conferences

March 2, 2021

Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress

February 18, 2021

Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences

February 8, 2021

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

February 3, 2021

Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock

February 1, 2021

Revolution Medicines Announces Proposed Public Offering of Common Stock

January 5, 2021

Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference

November 12, 2020

Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress

October 24, 2020

Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Next page
Last page

Displaying 1 - 10 of 54

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2021 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063

Search Investor Relations